Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

about

Sequencing brain metastases and opportunities for targeted therapies.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?

P2860

Q39177404-CB26C48A-C08A-4993-8B60-2426FE221BC4 Q50043843-A529F504-487B-4102-BC5B-99513B33932A

P2860

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

Item

http://www.wikidata.org/entity/Q38715328

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

@en

type

Item

label

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

@en

prefLabel

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

@en

P1476

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

@en

P2093

Georg Pall

http://www.w3.org/2001/XMLSchema#string

Guenther Stockhammer

http://www.w3.org/2001/XMLSchema#string

Jan-Paul Bohn

http://www.w3.org/2001/XMLSchema#string

Michael Steurer

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

P2888

s11523-015-0414-5

P304

263-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-015-0414-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048160085

http://www.w3.org/2001/XMLSchema#string

P698

26822319

http://www.w3.org/2001/XMLSchema#string

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

about

P2860

P2860

Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698